You centered on Mexico,...but I also included Canada,... and let's not forget the current action is in Europe.
2005-08-02 07:24 ET - In the News
The Globe and Mail reports in its Monday edition that business development is the new buzzword at Vasogen, replacing drug research, as a 15-year odyssey to develop a novel treatment for artery and heart disease is nearing the finish line. The Globe's Leonard Zehr quotes chief executive officer David Elsley as saying, "Our focus on business development has intensified this year as we get ready for a possible launch of Celacade in Europe in 2006." Celacade is the company's unique "grey box" that zaps a sample of patient blood to reverse inflammation's chronic role in cardiovascular disease. "Then, we'll intensify our focus again for a possible launch in the United States in 2007," he added. To prepare for the transition, the company has moved into a larger head office and doubled its work force to 180 over the past two years, with the lion's share of the increase in its business development, marketing and insurance reimbursement group. Getting Celacade, which has cost about $150-million (U.S.) to develop and test, into the hands of cardiologists and large heart-failure clinics would represent a major achievement for Vasogen. Vasogen is expected to be cash-flow positive next year. |
